CN102579463A - Application of glibenclamide compound in preparation of information therapy medicament, method for preparing information therapy medicament, and novel drug prepared with method - Google Patents
Application of glibenclamide compound in preparation of information therapy medicament, method for preparing information therapy medicament, and novel drug prepared with method Download PDFInfo
- Publication number
- CN102579463A CN102579463A CN201110020994XA CN201110020994A CN102579463A CN 102579463 A CN102579463 A CN 102579463A CN 201110020994X A CN201110020994X A CN 201110020994XA CN 201110020994 A CN201110020994 A CN 201110020994A CN 102579463 A CN102579463 A CN 102579463A
- Authority
- CN
- China
- Prior art keywords
- glibenclamide
- medicine
- container
- information
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of a glibenclamide compound in preparation of an information therapy medicament, a method for preparing the information therapy medicament, and a novel drug prepared with the method. The information therapy medicament is not in direct contact with a human body during treatment, the components of the medicament is not consumed, only medicament information is utilized for physical therapy, so that the chemical treatment effect can be achieved, the therapeutic window is enlarged by more than a thousand times, and the side effect of chemical treatment is avoided. After the glibenclamide is used as the information therapy medicament, the content of effective components of the glibenclamide is not changed, so that the glibenclamide can be used as a conventional preparation in chemical treatment for secondary effective use.
Description
Technical field
The present invention relates to drug world, be specifically related to the novel medicine of a kind of glibenclamide.
Background technology
Chemical compound glibenclamide (Glibenclamide) is N-[2-[4-[[[(hexamethylene is amino) carbonyl] amino] sulfonyl] phenyl] ethyl]-2-methoxyl group-5-chlorobenzamide, chemical molecular formula C
23H
28CLN
3O
5S, molecular weight 491.01.Character is a white crystalline powder, and almost odorless is tasteless.In water or ether, do not dissolve, at chloroform part omitted dissolving, slightly soluble in methanol or ethanol.Fusing point is 170-174 ℃.Glibenclamide is a blood sugar lowering, clinically is used to treat diabetes.The medicine preparation of glibenclamide has tablet, capsule etc.Known glibenclamide medicine all is the purposes as chemotherapeutic agent, is to let chemical compound glibenclamide molecule get into human body (administered through oral absorbs and gets into blood), is distributed to each tissue, produces pharmacological action through drug molecule at the intravital chemical reaction of people.Glibenclamide is as the chemotherapeutic agent purposes in the prior art; Unvanquishable defective of settled the present is arranged; The one, to the toxic and side effects of human body, its tedious untoward reaction comprises hypoglycemia and severe hypoglycemia; But weight person's threat to life, gastrointestinal tract nausea and vomiting, loss of appetite, diarrhoea, jaundice, abnormal liver function, anemia, thrombocytopenia, anaphylaxis, arthralgia, intramuscular pain, vasculitis reaction etc.; The 2nd, the treatment window is little, owing to there is the toxic and side effects to human body, the effective dose that can use is very little, has limited therapeutic effect, and the maximum dose of oral administration is a 5mg, and 15mg on the one surmounts maximum dose and then can cause poisoning; The 3rd, have only a kind of purposes of chemotherapeutic agent, medicine gets into human body and is promptly decomposed or drainage by metabolism, can not use by secondary.
Summary of the invention
The objective of the invention is to rediscover a kind of new purposes, new method that can overcome its defective, create a kind of unprecedented novel product to the defective of chemical compound glibenclamide as the chemotherapeutic agent purposes.
In order to accomplish the object of the invention, the present invention adopts following technical scheme:
Get new synthetic glibenclamide raw material (1) medicine (meeting the NF standard) powder, also can add carrier auxiliary material, encapsulate with porous carrier material (2); Insert encapsulation in the container (4) that is furnished with hole (5) again, go up the assembling suspender, process glibenclamide information therapy medicine agent (12) at the container that is furnished with hole (5) (4); Be placed on body surface face messenger drug object distance skin 1-10mm (preferred 2mm) during treatment and locate suspension (fix) and use, preferred human umbilical region position makes a lagging skin of hole (5); Use every day once, use 4-6 hour at every turn, or every day 2 times; Each 2-3 hour, through glibenclamide drug information and human body information receptor response, medicament information naturopathy method; Reach therapeutic effect, rather than reach therapeutic effect through glibenclamide drug substance molecule entering human body and human body material receptor response.Glibenclamide is as a kind of information therapy drug use in the present invention, rather than uses as a kind of chemotherapeutic agent.Therefore; Glibenclamide as the information therapy drug use after owing to make the information Drug therapy and do not consume the glibenclamide material, do not influence glibenclamide content; Make the medicine material after the information Drug therapy is used a course of treatment; Can also use as chemotherapeutic agent for the second time, process conventional preparations such as oral formulations, injection and Transdermal absorption and be used for chemotherapy, have the therapeutic effect of common glibenclamide preparation.
New synthetic glibenclamide raw material (1) powder of the present invention, be meant accomplish the synthetic production time 3 months with interior glibenclamide medicine material, press dry product calculating, contain C
23H
28CLN
3O
5S is no less than 99.0%.
Carrier auxiliary material of the present invention is the natural mineral tourmaline functional crystal material, and any that comprises magnesium ferrum elbaite, tsilaisite, uvite, buergerite is crushed to ultra-fine, particle diameter 100nm-10um.
Porous carrier material of the present invention (2) is micropore non-woven fabrics, microporous fibre cloth, micropore paper, cellular plastic etc., and its micropore size and density are not leaked powder body for well breathing freely.
The container (4) that is furnished with hole (5) of the present invention is box body, bag or the other forms of container (4) of circular, oblate type or other shapes, is furnished with some holes (5), hole (5) diameter 0.3-3mm in the one side or the several times of container (4).
Suspender of the present invention is to utilize a fulcrum, and with the hanger or the fixture of the unsettled support of medicine, these hangers or fixture are common magnetic sheet (7), rope, band, bag, frame, hook or stickup etc.Suspender is that magnetcisuspension is hung (card) (8) or rope (band) suspension arrangement (11).Described magnetcisuspension is hung the method for preparing of (card) (8) containers (4) box: the manufacture method that magnetcisuspension is hung (card) (8) containers (4) box is: empty diameter 5-10cm in producing with the mould of plastics injection moulding; Oblate container (4) box of height 0.5-1.5cm; The hole (5) of the some diameter 0.1cm of outside cloth of container (4) box bottom; Container (4) box top underside concave surface is inserted the magnetic sheet (7) of 500-1500 Gauss magnetic force; The vinyl cover (6) that on container (4) box top surface, adds an equal sizes in addition, vinyl cover (6) inner face concave surface is inserted the magnetic sheet (7) of 500-1500 Gauss magnetic force, forms magnetic attraction with the magnetic sheet (7) of inserting in container (4) box top vinyl cover (6) is held; In container (4) box top and vinyl cover (6), be provided with the sub-tooth post mouth (9) of ability interlock, so that fixed container (4) box and vinyl cover (6).Said rope (band) suspension arrangement (11) is that the container (4) that magnetcisuspension is hung (card) (8) is not installed, and rope (band) suspension arrangement (11) is installed is connected.
Information therapy medicine of the present invention agent (12) be the drug pack relief its apart from human body skin 1-10mm; The dosage form that preferred 2mm hanging shape uses; Do not allow drug substance directly to contact human body skin, do not have the drug substance composition to absorb, only through drug information superconduction treatment disease.
Method for preparing of the present invention comprises: 1. take by weighing new synthetic glibenclamide raw material (1) medicine (C in 3 months
23H
28CLN
3O
5S content is not less than 99.0%); 2. optionally add the carrier auxiliary material of drug weight 1-10%, preferred dosage 5%, described carrier auxiliary material are natural mineral tourmaline functional crystal material superfine powder, particle diameter 100nm-10um; 3. it is abundant to drop into batch mixer normal temperature and pressure mechanical mixture, processes the drug information filler, and blended temperature 10-25 ℃, preferred 20 ℃, blended time 30-60 minute, preferred 45 minutes; 4. will mix sufficient filler and drop into the powder body racking machine, by the weight of every bag 10-50 gram, the dosage of preferred 25 grams with drug information filler porous carrier material (2) bag of packing into, seals with heat mode such as melt, and processes drug information filler bag (3) one by one; The container (4) of 5. the drug information filler bag (3) after the subpackage being packed into and being furnished with hole (5) is adorned 1 bag in each container (4); 6. adding the suspender combination on the container (4) processes.
For the ease of understanding the present invention, below term used herein is done further to explain.
Term used herein " information therapy medicine " is a kind of medicine of treatment non-chemically.Chemotherapeutic agent is that the drug substance composition comprises that through the approach of routine direct injection gets into blood of human body, oral absorption gets into blood or gets into blood through skin Transdermal absorption and mucosa absorption; And then be distributed in each tissue system of human body; Produce pharmacological action through drug molecule at the intravital chemical reaction of people, drug molecule is decomposed in human body, metabolism and drainage.Do not get into human body and do not contact human body during the information therapy Drug therapy yet; Need not consume the drug substance composition; Do not have the medicine molecule to get into human body, only utilize drug molecule information to regulate function of human body, reach therapeutic effect; Thereby in human body, not having the drug molecule metabolism, the material composition less than this medicine is also detected in the treatment back in human body or in the slop.This also a kind of new Therapeutic Method, i.e. drug information physiotherapy.
Term used herein " application of medicine secondary " or " secondary use " are meant that medicine can be used by secondary application or secondary.The present invention has found the information therapy purposes of the medicine that general knowledge can't be understood; Owing to do not have drug substance to be absorbed by the body and utilize as the information therapy medicine, the drug information treatment only is used in drug information, does not consume drug substance; The material composition of medicine does not change; Effective content does not reduce, and that is to say that medicine still meets the standard of chemotherapy needs, thereby as making effectively therapeutic use of chemistry by secondary after the information therapy purposes; Be that the medicine secondary is effectively used or use, do not influence the conventional therapy effect of pharmaceutical chemistry treatment.
Term of the present invention " treatment window ", the i.e. ratio of curative effect and side effect.To the understanding of treatment window size, if medicine differs greatly to the affinity in target spot and side effect site, and stronger to the target spot affinity, its " treatment window " (Therapeutic window) is just greatly so.The treatment window enough greatly the time, can increase by 500 dosage, 10 times, even more than 50 times, and serious adverse can not appear.Under the ideal situation, as new drug development person, doctor or a patient, you can hope that the patient takes medicine the treatment window more than 100 times or 500 times is arranged between true target spot and other action sites.What remember is, decision is during to a stack of people's dosage, consider that the individual variation of drug metabolism speed maybe be up to 10 times, and concerning some patient, one is merely 10 times the treatment window window that is equal to nothing.In fact the conventional chemical medicine of chemical compound glibenclamide treatment window is just very little, and the chemical compound glibenclamide is as the chemotherapy window only about 10 times, and can reach more than thousand times as information therapy Drug therapy window.
Behind the clinical increase of the present invention treatment window, the disease of treatment comprises and is used to treat diabetes etc.
The present invention is instead of chemical medicine treatment disease directly, can also enlarge its chemotherapy window as the chemotherapeutic agent synergist, strengthens its chemotherapeutic agent therapeutic effect and does not increase the chemotherapeutic agent toxic and side effects.
The present invention has found the new purposes of chemical compound glibenclamide as the information therapy medicine, has created a kind of brand-new glibenclamide medicine novel form, has very obvious improvement meaning:
1, the present invention has enlarged the treatment window of glibenclamide greatly.Because the present invention finds the method for glibenclamide information therapy; There is not glibenclamide material composition to get into human body when using the glibenclamide treatment; Thereby avoided the disagreeable toxic and side effects of glibenclamide; The treatment window that makes glibenclamide can improve the therapeutic effect of glibenclamide from having only 10 times can expand to more than thousand times, overcomes the side effect of glibenclamide.Simultaneously, when the glibenclamide preparation curative effect of using the known conventional dosage form is undesirable, increase use of the present invention, can strengthen the curative effect of glibenclamide and do not increase its toxic and side effects, become the chemotherapeutical synergist of glibenclamide.
2, the present invention has realized the secondary application of glibenclamide medicine unprecedentedly; Glibenclamide is as the information therapy drug use; Brought into play effective therapeutical effect, effectively use a course of treatment (1 to 2 months is 1 course of treatment) first after, can also secondary use and use as chemotherapeutic agent again; Can reduce the Drug therapy cost greatly, increase the use value of medicine.Owing to recycling, reduce drug waste and save resource medicine simultaneously, reduce the environmental pollution that pharmaceuticals industry brings glibenclamide.
3, the present invention need not use non-pharmaceutical compositions such as a large amount of adjuvants that existing conventional medicine preparation has to add in order to guarantee pharmaceutical compositions to get into the effectively stable of human body or auxiliary agent, stabilizing agent, excipient; Also avoided these non-pharmaceutical compositions to get into the adverse effect of human body to human body; Also save simultaneously a large amount of auxiliary material, reduce pharmaceutical preparation consumption.
4, the present invention use simply, convenient, safe, reliable, acceptant.Particularly for old, weak, child, or sicken for consciousness, dysnoesia, behavior disorder patient be more suitable.
5, the present invention can also reduce the trouble of hospital care personnel administration, alleviates its labor intensity, saves the human resources.
Description of drawings
Fig. 1 filler bag sketch map
1, raw material
2, porous carrier material
3, filler bag
Fig. 2 container sketch map
4, container
5, hole
6, vinyl cover
7, magnetic sheet
8, magnetcisuspension is hung (card)
9, sub-tooth post mouth
10, lid
Fig. 3 container top inner face sketch map
Fig. 4 container top outside sketch map
Fig. 5 medicine information treatment medicine agent sketch map
11, rope (band) suspension arrangement
12, information therapy medicine agent
The specific embodiment
Help to understand the present invention through following examples, but do not limit content of the present invention.
Embodiment
Take by weighing glibenclamide raw material (1) by following weight: glibenclamide raw material (1) (content >=99%) 200 grams; Raw material (1) is dropped into racking machine; Be distributed into 10 bags with the micro-porous permeable paper bag by every bag of net weight 20 gram, heat is melted and is sealed, and processes glibenclamide drug information filler bag (3).Simultaneously, other makes magnetcisuspension and hangs 10 in (card) (8) containers (4) box.The manufacture method that magnetcisuspension is hung (card) (8) containers (4) box is: empty diameter 5-10cm in producing with the mould of plastics injection moulding; Oblate container (4) box of height 0.5-1.5cm; The hole (5) of the some diameter 0.1cm of outside cloth of container (4) box bottom; Container (4) box top underside concave surface is inserted the magnetic sheet (7) of 500-1500 Gauss magnetic force; The vinyl cover (6) that on container (4) box top surface, adds an equal sizes in addition, vinyl cover (6) inner face concave surface is inserted the magnetic sheet (7) of 500-1500 Gauss magnetic force, forms magnetic attraction with the magnetic sheet (7) of inserting in container (4) box top vinyl cover (6) is held; In container (4) box top and vinyl cover (6), be provided with the sub-tooth post mouth (9) of ability interlock, so that fixed container (4) box and vinyl cover (6).10 magnetcisuspensions are hung the box-packed method of going into content of (card) (8) containers (4): open container (4) lid (10); Each container (4) is box-packed goes into a bag glibenclamide drug information filler bag (3); Cover lid (10) and gluingly connect sealing with 502, process glibenclamide information therapy medicine agent (12).
Clinical use glibenclamide information therapy medicine agent (12) and oral glibenclamide sheet curative effect comparative observation, the result is following:
1. data and method
1.1 physical data
Select the type 2 diabetes mellitus patient as object of study, all meet WHO diagnosis of diabetes standard in 1999, i.e. diabetic symptom+random time blood glucose >=11.1mmol/L or fasting glucose >=7.0mmol/L or OGTT2h >=11.1mmol/L.Male 12 examples among the 20 routine patients, women 8 examples, age 26-76 year, average 49.5 ± 5 years old; Medical history 4-23, average 12.5; All patients do not use antidiabetic drug, complication such as hepatic and renal function and cardiac function Non Apparent Abnormality, no serious albuminuria, diabetic renal papillary necrosis in selected preceding 1 month.The empty clothes of inspection blood glucose (9.23-23.14) mmol/L, 2H blood glucose (10.4-32.6) mmol/L after the meal.Wherein complicated hypertension, coronary heart disease 8 examples merge disorders of lipid metabolism 6 examples, fat and overweight 10 examples.All patients are divided into each 10 example of observation group and matched group at random, and aspect comparisons such as two groups of patient's age, sex, the course of disease, and different not statistically significant (P＞0.05) have comparability.
1.2 Therapeutic Method
The treatment group gives glibenclamide information therapy medicine agent treatment, and every day, umbilical part hung once, and each 5 hours, there is the one side of hole to paste umbilical part skin, matched group gives the glibenclamide treatment, and 2.5mg 30min before the meal is oral, and 1 time/d, 2 months courses of treatment.Observe and compare two groups of treatment front and back fasting glucose (FBG), the variation of 2h blood glucose (2hPPG), BIM, blood fat, blood pressure, and untoward reaction situation after the meal.
1.3 criterion of therapeutical effect
Be divided into according to China's " Clinical Researches of New Drugs guideline " standard: produce effects: FBG≤7.2mmol/L or reduce more than 30.0%; 2h PBG≤8.3mmol/L or reduce more than 30.0%.Effectively: FBG≤8.3mmol/L or reduction 10.0%-29.0%; 2h PBG≤10.0mmol/L or reduction 10.0%-29.0%. are invalid: FBG and 2hPBG no change or reduction＜10.0%.
1.4 statistical procedures
All The data SPSS10.0 statistical softwares handle, and measurement data is with mean ± standard deviation
Expression is adopted t check (adopting paired t-test before and after the treatment), the relatively employing X of rate
2Check.
2 results
2.1 two groups of clinical efficacies relatively
See that the routine total effective rate of table 1. treatment table 10 is 90.0% (9/10), apparently higher than matched group 80.0% (8/10), two groups of total effective rates compare, and difference has statistical significance (P＜0.05).
Table 1 liang group clinical efficacy is [n (%)] relatively
2.2 FBG, 2hPBG, BMI are relatively before and after two groups of treatments
See table 2. liang group treatment after 2 months, FBG, 2hPBG, BMI all obviously reduce (P＜0.05), and the decline of treatment group is more obvious, but compare difference not statistically significant (P＞0.05) respectively before the treatment with after the treatment between two groups.
Table 2 liang group treatment front and back FBG, 2hPBG, BMI be
relatively
Annotate: relatively preceding with treatment,
#P＜0.05
2.3 blood fat, blood pressure are relatively before and after two groups of treatments
Two groups after treatment in 2 months, two groups blood lipids index TC, TG, HDL-C, LDL-C and blood pressure index S BP, DBP all change not obvious, in two groups of groups and between group relatively, difference not statistically significant (P＞0.05).See table 3.
Blood fat, blood pressure compare (
n-50) before and after the table 3 liang group treatment
2.4 two groups of adverse reaction rates relatively
The treatment group does not go out to see discomfort; 2 examples such as dizziness, stomach discomfort appear in matched group, and incidence rate of adverse reaction is 20%, all alleviate behind the symptomatic treatment to disappear.
Following to as glibenclamide raw material (1) the medicine assay data after information therapy drug use 1 course of treatment:
Chromatographic condition and system suitability test: use octadecylsilane chemically bonded silica to be filler; (get Ammonium biphosphate 1.725g from ammonium dihydrogen phosphate; Add water 300ml dissolving, regulate PH value to 3.5 ± 0.05 with phosphoric acid)-methanol (3: 5) is mobile phase, detecting wavelength is that the contrast solution 20ul that 300nm. gets under the related substance item injects chromatograph of liquid; The record chromatogram, each component peak sequence is followed successively by impurity I, impurity II, glibenclamide.Theoretical number of poles calculates by the glibenclamide peak and is not less than 5000, and the separating degree at impurity I and impurity II peak should meet the requirements.
Algoscopy: get the about 10mmg of raw material (1) sample that used for 1 course of treatment in glibenclamide information therapy medicine agent (12) box, the accurate title, decide, and puts in the 50ml measuring bottle; Add methanol 12ml; Supersound process makes the glibenclamide sample dissolution, releases to scale with the mobile phase weighing apparatus, shakes up; Precision is measured 20ul and is injected chromatograph of liquid, the record chromatogram; Other gets the glibenclamide reference substance, measures with method.Press external standard method with its content of calculated by peak area.
Result: raw material (1) the sample C that has used a month course of treatment in glibenclamide information therapy medicine agent (12) box
23H
28CLN
3O
5S content is 99.0%.
Claims (7)
1. the new purposes of chemical compound glibenclamide is characterized in that can be used for preparing the information therapy medicine, and described information therapy medicine is a kind of medicine of treatment non-chemically; Do not make medicine directly contact human body when promptly treating; Do not make drug molecule get into human body, do not consume the drug substance composition, only utilize drug molecule information to regulate function of human body; Medicament information naturopathy method; Reach therapeutic effect, when treatment, do not have the drug molecule metabolism in the human body, after treatment, detect material composition in human body or in the slop less than this medicine; As after information therapy drug use course of treatment, do not change the composition and the content of medicine, also can be used as chemotherapeutic agent and process conventional formulation (like oral formulations, injection, transdermal absorption formulation) secondary and effectively treat use.
2. new purposes according to claim 1 is to adopt chemical compound glibenclamide raw material (1) (content >=99.0%), need melt to seal with Different Weight packing and heat by treatment with porous carrier material (2) and process drug information filler bag (3); Insert the surface and be furnished with the container (4) of some holes (5); Suspension is fixed on the human body skin, and there is a lagging skin of hole (5) preferred human umbilical region position; Medicine is apart from skin 1-10mm; Preferred 2mm, the superconduction of medicament information is treated, and avoids the toxic and side effects of medicine.
3. new purposes according to claim 1; The information therapy medicine of preparation; Directly the instead of chemical medicine is treated disease; Can also enlarge its chemotherapy window as the chemotherapeutic agent synergist, strengthen its chemotherapeutic agent therapeutic effect and do not increase the chemotherapeutic agent toxic and side effects.
4. the chemical compound glibenclamide is used to prepare the method for preparing of information therapy medicine, it is characterized in that: 1. take by weighing new synthetic glibenclamide raw material (1) medicine (C in 3 months
23H
28CLN
3O
5S content is not less than 99.0%); 2. optionally add the carrier auxiliary material of drug weight 1-10%, preferred dosage 5%, described carrier auxiliary material are natural mineral tourmaline functional crystal material superfine powder, particle diameter 100nm-10um; 3. it is abundant to drop into batch mixer normal temperature and pressure mechanical mixture, processes the drug information filler, and blended temperature 10-25 ℃, preferred 20 ℃, blended time 30-60 minute, preferred 45 minutes; 4. will mix sufficient filler and drop into the powder body racking machine, by the weight of every bag 10-50 gram, the weight of preferred 25 grams with drug information filler porous carrier material (2) bag of packing into, is sealed with heat mode such as melt, and processes drug information filler bag (3) one by one; 1 bag in the container (4) of 5. the drug information filler bag (3) after the subpackage being packed into and being furnished with hole (5), each container (4); 6. adding the suspender combination on the container (4) processes.
5. glibenclamide raw material according to claim 4 (1), be accomplish the synthetic production time 3 months with interior glibenclamide medicine material (1), calculate by dry, contain C
23H
28CLN
3O
5S is no less than 99.0%; Said carrier auxiliary material is the natural mineral tourmaline functional crystal material, and any that comprises magnesium ferrum elbaite, tsilaisite, uvite, buergerite is crushed to ultra-fine, particle diameter 100nm-10um; Described porous carrier material (2) is micropore non-woven fabrics, microporous fibre cloth, micropore paper, cellular plastic etc., and its micropore size and density are not leaked powder body for well breathing freely; Described container (4) is box body, bag or the other forms of container (4) of circular, oblate type or other shapes, is furnished with some holes (5), hole (5) diameter 0.3-3mm in the one side or the several times of container (4); Described suspender is to utilize a fulcrum, and with the hanger or the fixture of the unsettled support of medicine, these hangers or fixture are common magnetic sheet (7), rope, band, bag, frame, hook or stickup etc.
6. chemical compound glibenclamide information therapy medicine agent (12); It is characterized in that forming by glibenclamide drug information filler bag (3), the container (4), the suspender that are furnished with hole (5); Said glibenclamide drug information filler bag (3) weight is 10 grams-50 grams, preferred 25 grams; The described container (4) that is furnished with hole (5), but multiaspect is furnished with some holes (5) or one side is furnished with some holes (5), and preferred container (4) bottom faces is furnished with some holes (5), hole (5) diameter 0.2-2mm, preferred 1mm; Described suspender; Be that magnetcisuspension is hung (card) (8) or rope (band) suspension arrangement (11); It is that recess is equipped with 500-1500 Gauss quantity of magnetism magnetic sheet (7) in container (4) top surface that magnetcisuspension is hung (card) (8); Cover the magnetic sheet (7) that (6) inner face recess is equipped with the 500-1500 Gauss quantity of magnetism in container (4) top plastic, rely on positive negative pole suction to hang on the device on the human body underwear; Said rope (band) suspension arrangement (11) is that the container (4) that magnetcisuspension is hung (card) (8) is not installed, and rope (band) suspension arrangement (11) is installed is connected.
7. chemical compound glibenclamide information therapy medicine agent according to claim 6 (12), clinical practice can increase more than thousand times treats window, and the disease of treatment comprises and is used to treat diabetes etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110020994XA CN102579463A (en) | 2011-01-18 | 2011-01-18 | Application of glibenclamide compound in preparation of information therapy medicament, method for preparing information therapy medicament, and novel drug prepared with method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110020994XA CN102579463A (en) | 2011-01-18 | 2011-01-18 | Application of glibenclamide compound in preparation of information therapy medicament, method for preparing information therapy medicament, and novel drug prepared with method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579463A true CN102579463A (en) | 2012-07-18 |
Family
ID=46469069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110020994XA Pending CN102579463A (en) | 2011-01-18 | 2011-01-18 | Application of glibenclamide compound in preparation of information therapy medicament, method for preparing information therapy medicament, and novel drug prepared with method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579463A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104098489A (en) * | 2014-07-10 | 2014-10-15 | 沈阳药科大学 | Micronized glibenclamide and composition thereof |
| CN104415435A (en) * | 2013-09-05 | 2015-03-18 | 北京中卫神农慢性病医学研究院有限公司 | Targeted information gas preparing device and purpose |
-
2011
- 2011-01-18 CN CN201110020994XA patent/CN102579463A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104415435A (en) * | 2013-09-05 | 2015-03-18 | 北京中卫神农慢性病医学研究院有限公司 | Targeted information gas preparing device and purpose |
| CN104098489A (en) * | 2014-07-10 | 2014-10-15 | 沈阳药科大学 | Micronized glibenclamide and composition thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102579463A (en) | Application of glibenclamide compound in preparation of information therapy medicament, method for preparing information therapy medicament, and novel drug prepared with method | |
| CN102579464A (en) | Application of compound glipizide in preparing information therapeutic drug, preparation method and prepared novel drug | |
| CN102579429A (en) | Application of indapamide compound in preparation of information therapy medicament, preparation method of indapamide compound, and prepared novel medicament | |
| CN103381140A (en) | Inosine-common salt composition and preparation method thereof | |
| KR20210006949A (en) | HC-1119 formulation and its manufacturing method and use | |
| US20140291197A1 (en) | Drug Suspension Agent and Method of Manufacture Thereof | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN102600176A (en) | Application of nilestriol compound in preparing information treatment drug, preparation method and prepared novel drug | |
| CN102872354A (en) | Application of composition Xiaoke pills in preparation of information intervention agent, preparation method of information intervention body and product | |
| CN102579407B (en) | Preparation method for indapamide microsphere sustained release capsules | |
| CN102600117A (en) | Application and preparation method of ambroxol hydrochloride in preparation of information therapeutic drug and novel drug prepared by preparation method | |
| CN102600147A (en) | Application of compound omeprazole in preparation of information treatment drug, preparation method of compound omeprazole, and prepared novel drug | |
| CN102600118A (en) | Application and preparation method of sibutramine in preparation of information therapeutic drug and novel drug prepared by preparation method | |
| CN102283926A (en) | Preparation technology and production method for novel integrated dosage form of liver fire-purging and stomach-regulating pill | |
| CN102600166A (en) | Application of allopurinol compound in preparing information treatment drug, preparation method and prepared novel drug | |
| CN102600160A (en) | Application of zopiclone compound in preparing information treatment drug, preparation method and prepared novel drug | |
| CN102600149A (en) | Pharmaceutical composition for treating diabetes | |
| CN102600168A (en) | Application of compound citric acid sildenafil in preparing information therapeutic medicament as well as preparation method thereof and novel medicine prepared by using compound | |
| CN102670501B (en) | Orally taken vitamin K1 lipid emulsion | |
| CN102600169A (en) | Application of compound mosapride in preparing information therapeutic medicament as well as preparation method thereof and novel medicine prepared by using compound | |
| CN102600151A (en) | Application of desloratadine compound in preparing information medicine, preparation method and prepared novel drug | |
| CN102600157A (en) | Application of dextromethorphan compound in preparing information treatment drug, preparation method and prepared novel drug | |
| CN102600133A (en) | Application of compound levetiracetam in preparing information therapeutic medicament as well as preparation method thereof and novel medicament prepared by using compound | |
| CN102600136A (en) | Use of compound thiamazole in preparation of information therapy medicine, preparation method of information therapy medicine, and prepared novel medicine | |
| CN102600150A (en) | Application of paroxetine compound in preparing information treatment drug, preparation method and prepared novel drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120718 |